Technology Holdings Unveils the 'TH Growth and Exit Strategy Report' for your Tech Services, Consulting, BPO or Technology Business: Get a Customised Exit Readiness, Recapitalization and Growth Strategy Report in Minutes Powered by Strat
Technology Holdings (TH), an award-winning global boutique investment bank with a presence in 12 countries across 5 continents, proudly announces the launch of the ‘TH Growth and Exit Strategy Report.’ This innovative report is designed specifically for businesses in IT Services, Consulting, Professional Services, Business Process Management, Technology and SaaS.
In just a few clicks, recipients will receive a customised report directly to their inbox, detailing their exit or recapitalization readiness and providing tailored recommendations for growth strategies. The report leverages TH’s 24 years of mergers and acquisitions, buy-out and growth advisory expertise and experience working with companies of all sizes combined with insights from management consultants.
Click here to complete the survey and receive the ‘TH Growth and Exit Strategy Report’, tailored for your business.
Using AI driven technology powered by Strat, Technology Holdings’ M&A experts have designed the survey to help businesses worldwide gain valuable insights into their current operational state and provide a roadmap for improving their business practices to attract potential investors or buyers. Upon completion, participants will receive a report with a “fit for sale” score, which is judged based on five sections of the report outlined below:
- Financial Performance Overview: An analysis of a company’s financial health, showcasing trends in revenue and profitability margins. The section illustrates the company's capacity for sustainable financial success and growth potential.
- Market Positioning and Value Proposition: This section provides insights into a company’s product offerings, highlighting competitive advantages such as brand reputation and commitment to innovation, and suggestions for improvement are provided, to better meet market demands.
- Client Landscape: A comprehensive overview of the client base, including demographics, retention rates, and revenue contributions. The section emphasizes the importance of client satisfaction and identifies strategies for enhancing relationships and feedback mechanisms.
- Operational Effectiveness: Evaluations of the operational model of a company, detailing the strengths and areas for improvement. The section discusses customer management processes, technology investments, and team dynamics, offering recommendations to optimize performance and efficiency.
- Strategic Initiatives for Growth: Initiatives to drive future growth, including market expansion, enhanced digital marketing efforts, and employee development investments. These strategies are aimed at positioning companies for long-term success and increased market share.
Vivek Subramanyam, Founder and CEO of Technology Holdings, stated, “We’re excited to introduce the ‘TH Growth and Exit Strategy Report,’ our ‘Management Consultant in a Box’ tool designed to help businesses maximize value, minimize risk, enhance growth strategy, and prepare for a successful exit or recapitalization. We appreciate the support from the team at Strat in creating this innovative tool, which enables businesses to receive a customised and comprehensive report in just minutes.”
About Technology Holdings
Technology Holdings (TH) is a global boutique investment bank dedicated to delivering M&A and capital raising advisory services exclusively to technology services, software, consulting, healthcare, and business process management companies with enterprise values ranging from $25 million to $500 million USD. Established in 2000, Technology Holdings has a team of over 130 employees and a global presence in 12 countries across 5 continents, and a track record of closing transactions in 24 countries.
About Strat
Strat uses AI-driven technology designed to help businesses think strategically and focus on what truly matters. Strat has a suite of digital products that use predictive analytics and collective intelligence to set direction, pinpoint key success factors, and craft tailored plans that empower companies to win in competitive markets. Fully self-serve and accessible anytime, anywhere, the platform equips teams with tools, workflows, and frameworks to address their most pressing strategic issues while fostering collaboration and driving alignment. Strat is the technology arm of Rygur consulting, a boutique firm specialising in innovative solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112361126/en/
Contacts
Haleigh Dhaou
PR Manager
haleigh@technologyholdings.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom